Mechanisms of action of PDE5 inhibition in erectile dysfunction

被引:0
|
作者
J D Corbin
机构
[1] Vanderbilt University School of Medicine,Department of Molecular Physiology and Biophysics
关键词
phosphodiesterase inhibitors; vasodilator agents; cyclic GMP; impotence; penile erection;
D O I
暂无
中图分类号
学科分类号
摘要
A spinal reflex and the L-arginine–nitric oxide–guanylyl cyclase–cyclic guanosine monophosphate (cGMP) pathway mediate smooth muscle relaxation that results in penile erection. Nerves and endothelial cells directly release nitric oxide in the penis, where it stimulates guanylyl cyclase to produce cGMP and lowers intracellular calcium levels. This triggers relaxation of arterial and trabecular smooth muscle, leading to arterial dilatation, venous constriction, and erection. Phosphodiesterase 5 (PDE5) is the predominant phosphodiesterase in the corpus cavernosum. The catalytic site of PDE5 normally degrades cGMP, and PDE5 inhibitors such as sildenafil potentiate endogenous increases in cGMP by inhibiting its breakdown at the catalytic site. Phosphorylation of PDE5 increases its enzymatic activity as well as the affinity of its allosteric (noncatalytic/GAF domains) sites for cGMP. Binding of cGMP to the allosteric site further stimulates enzymatic activity. Thus phosphorylation of PDE5 and binding of cGMP to the noncatalytic sites mediate negative feedback regulation of the cGMP pathway.
引用
收藏
页码:S4 / S7
相关论文
共 50 条
  • [1] Mechanisms of action of PDE5 inhibition in erectile dysfunction
    Corbin, JD
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2004, 16 (Suppl 1) : S4 - S7
  • [2] PDE5 Inhibitors for Erectile Dysfunction
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2012, 54 (1383): : 10 - 11
  • [3] PDE5 inhibitors beyond erectile dysfunction
    P Sandner
    J Hütter
    H Tinel
    K Ziegelbauer
    E Bischoff
    [J]. International Journal of Impotence Research, 2007, 19 : 533 - 543
  • [4] Oral PDE5 Inhibitors for Erectile Dysfunction
    Murphy, Matthew
    Demers, Jill M.
    Ostroff, Marissa L.
    Ostroff, Jared L.
    [J]. US PHARMACIST, 2018, 43 (06) : 29 - 33
  • [5] PDE5 inhibitors beyond erectile dysfunction
    Sandner, P.
    Huetter, J.
    Tinel, H.
    Ziegelbauer, K.
    Bischoff, E.
    [J]. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2007, 19 (06) : 533 - 543
  • [6] PDE5 inhibitors and satisfaction of patients with erectile dysfunction
    Cour, F.
    [J]. PROGRES EN UROLOGIE, 2008, 18 (08): : 542 - 542
  • [7] PDE5 inhibitors: targeting erectile dysfunction in diabetics
    Francis, Sharron H.
    Corbin, Jackie D.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2011, 11 (06) : 683 - 688
  • [8] Patterns of PDE5 inhibitor use in patients with erectile dysfunction
    Katherine Sole
    [J]. Nature Clinical Practice Urology, 2006, 3 (1): : 6 - 6
  • [9] Psychological Predictors of PDE5 Inhibitors in Vasculogenic Erectile Dysfunction
    Palmas, Artur
    Pascoal, Patricia
    Nobre, Pedro
    [J]. INTERNATIONAL JOURNAL OF SEXUAL HEALTH, 2019, 31 : A568 - A568
  • [10] Mirodenafil: a new PDE5 inhibitor for the treatment of erectile dysfunction
    [J]. Nature Clinical Practice Urology, 2009, 6 (2): : 60 - 60